ShareTreck: Jeff Galvin Weighs in on Addimmune’s Launch and AGT103-T Updates

Addimmune™ CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to discuss the company’s launch as well as updates on AGT103-T, Addimmune’s HIV therapeutic. Following a successful Phase 1 clinical trial, will build AGT’s success, accelerating the clinical development with dedicated investment and singular focus on HIV. 

Be Part of Our Mission to Make an Impact

Sign up for our newsletter and follow our journey to potentially eradicate HIV with our gene therapy.

Subscribe Here!


Scroll to Top